Kornimate/medical-research-clean huggingface dataset:
physical activity experiment on male prostate cancer patients

Conditions: Cancer Prostate

Summary: prostate cancer is the most common cancer in france (56,841 cases in 2012). although the benefits of physical activity (pa) in cancer patients are currently well established in the scientific literature, several studies have shown that this population is not sufficiently active. strengthen patient adherence to prevention counseling by the physical activity (pa) is emerging as a new challenge for personalized treatment in oncology. in order to encourage the engagement and maintenance in a regular pa of cancer patients, first, their experiences of physical activity (pa) practice should be considered and their initial social representations of the practice considered. secondarily, it is also important to identify health professionals who retain a key role in defining the framework, objectives and means of action to promote lifestyle changes towards a more active lifestyle. in addition, peer mentoring appears to offer promising perspectives for promoting adherence and long-term maintenance in physical activity (pa) of cancer patients.

the main objective of this project is to measure the adherence of prostate cancer patients to a physical activity program with a tracking of the motivation by a pair.

Eligibility criteria:
inclusion criteria for patient in step1, 2 and 3: * major patient followed for prostate cancer: * located or locally advanced, * metastatic and / or resistant to castration and chemotherapy. * cancer diagnosed at least 1 year ago * patient affiliated or beneficiary to social security * signed informed consent. in more, step 2 = patient with physical activity for at least 1 year exclusion criteria: for step 1= in the course of cancer treatment (excluding hormonal therapy) for step 2= patient in sedentary lifestyle for step 3= * in the course of cancer treatment (excluding hormonal therapy) * cardiac or respiratory conditions contraindicating physical activity

Keywords: prostate cancer physical activity activity actigraph peer program sports medicine
tavns-paired breastfeeding to improve breastfeeding at discharge

Conditions: Premature Birth; Breastfeeding, Exclusive; Feeding; Difficult, Newborn

Summary: investigators aim to improve the skills of premature or sick term infants in breastfeeding by boosting motor learning with transcutaneous vagus nerve stimulation. investigators will recruit 10 premature, ≥ 35 weeks gestational age, or convalescing sick term infants admitted to the nicu at musc to participate in this study. infants will receive tavns treatments once a day with breastfeeding's for up to 14 days. before each treatment, the researcher will determine how much electrical stimulation is needed for the infant to feel a slight tingle without discomfort, and during daily treatment paired with breastfeeding the infant will continue to receive this level of electrical stimulation, coinciding with latching and sucking, repeated over the duration of the feed. investigators will collect information about the pre- and post-feed weights, the length of time for each feed, and observations of latch, suck, and swallow techniques by the infant from parents and the lactation consultant. investigators will also evaluate parental satisfaction associated with their infant's ability to breastfeed after tavns by providing parental satisfaction surveys at the beginning, after 1 and 2 weeks, and at 3 months after the end of the study to assess infants' progress in and maintenance of breastfeeding abilities. if the pairing of breastfeeding with tavns is able to result in improved outcomes of effective breastfeeding in infants in the neonatal intensive care units, this intervention could be further utilized by nicus to increase the rate of premature and sick term infants who are successfully able to breastfeed at the time of discharge and maintain breast feeding longer after discharge. this would allow premature infants to acquire the many benefits of breastmilk as well as contribute towards the strengthening of the maternal-infant bond that breastfeeding has been shown to enhance.


Eligibility criteria:
inclusion criteria: * infants ≥ 35 weeks post-menstrual age, * clinically stable, without significant respiratory support, * deemed safe to breastfeed by ot/slp/lactation, * maternal interest in breastfeeding, * are not breastfeeding well despite the assistance of a lactation consultant. exclusion criteria: * cardiomyopathy, * unstable bradycardia, * significant respiratory support, * absent maternal interest in breastfeeding, or infant or mother with contraindications to breastfeeding such as infantile galactosemia, * maternal hiv without adequate viral suppression, * maternal illicit drug use.
crave crush behavioral study

Conditions: Obesity

Summary: the purpose of the research is to determine if participants who take "crave crush" will report lower cravings and palatability ratings of candy as compared to subjects who receive the placebo. participants are self-selected university students who pass our table and verbally agree to participate in a research study about taste preferences. data will be recorded anonymously.

when students approach the table, research assistants will ask them to choose their favorite kind of candy from an assortment. they will ask the subjects to rate their craving for the candy before they taste it. after they try the candy, the research assistants will ask them to rate its palatability. then they will rate their craving for another piece of candy. a research assistant will flip a coin to determine whether the subject will receive crave crush or placebo. while the crave crush or placebo is dissolving in the mouth, the students will fill out a short questionnaire with an identification number. the questionnaire will ask for their age, gender, ethnicity, approximate height and weight, and a few questions about their dietary habits. after the tablet dissolves, research assistants will ask the students to rate their craving for another piece of candy. research assistants will ask participants if they would like another piece of candy and have them assess palatability again. the process of offering a piece of candy and asking subjects to rate palatability will occur up to five times. finally, subjects will be asked if they would like to take a few pieces of candy for the road and if they say yes, the number of pieces they take with them will be noted. the study activities should last no more than 5-10 minutes per participant.

Eligibility criteria:
inclusion criteria: * university student, having eaten within the last hour, having slept within two hours of their normal amount exclusion criteria: -
ocular complications of mpox in the democratic republic congo

Conditions: Monkeypox; Mpox (Monkeypox)

Summary: this is an observational study in which patients diagnosed with mpox will be enrolled, will undergo standard ophthalmological examinations of their eyes to see if there are any complications of mpox. the study will primarily assess the presence of ophthalmological signs and symptoms at enrollment.

this is an observational study in which patients diagnosed with mpox will be enrolled in two clinics in remote settings in the dr congo (tunda and kole general hospital) where mpox outbreaks are ongoing. after providing informed consent, participants will undergo standard ophthalmological examinations of their eyes to see if there are any complications of mpox. this includes history taking, clinical examination, technical examinations such as a dilated fundoscopic exam, a fluorescein test and a schirmer test, and a conjunctival swab for tear collection for monkeypox virus (mpxv) detection. pictures of the anterior and posterior segment will also be taken to aid later verification and interpretation of the study findings. if they are hospitalised for mpox (for clinical reasons or as part of their participation in another ongoing clinical trial at the study sites), they will be followed up for 14 days and examined during an unscheduled visit in the case of new or worsening severe issues. otherwise, patients are followed up at day 14 (for those hospitalised), day 28 and day 59. study participants will receive the same supportive eye care as non-study participants. study participants will be compensated for their time lost and for transportation to the clinic. the study will primarily assess the presence of ophthalmological signs and symptoms at enrollment, but also aims to describe the complications of mpox that may arise after that point in time.

Eligibility criteria:
inclusion criteria: * patient of any age or gender with laboratory-confirmed infection with mpxv * laboratory confirmation of mpxv infection less than 48 hours before inclusion * patient or culturally acceptable representative is willing and able to give informed consent or assent for participation in the study exclusion criteria: * patients for whom, in the judgment of the recruiting physician, participation in the study would interfere with routine optimal clinical care.

Keywords: ophthalmology complications
gut microbiome mediated effects of inulin supplementation on mineral and bone metabolism in hemodialysis patients

Conditions: Bone Diseases, Endocrine; Nutritional and Metabolic Diseases

Summary: the overall objective of the study is to examine the changes within the gut microbiome after the supplementation of inulin and its effect on markers of mineral metabolism and bone turnover.

in this randomized controlled cross-over study, twenty hd patients (10 male/10 female, aged 20-80) will be recruited from local dialysis clinics in champaign-urbana, il. after baseline testing, patients will be randomized to the intervention group or placebo group (maltodextrin). patients will consume inulin (females 10g/day, males 15g/day) or maltodextrin (females 10g/day, males 15g/day) for one month, rest for two weeks (washout period), and continue with the other treatment (either inulin or maltodextrin) for another month. outcomes will be assessed at the beginning of each period and after a month of supplementation at both periods.

Eligibility criteria:
inclusion criteria: * receive hd therapy 3 days per week and for at least 3 months exclusion criteria: * sustained hypercalcemia (\>3months). * previous major gastrointestinal disease diagnosis (e.g., inflammatory bowel disease and celiac disease). * antibiotic treatment \< 2 weeks prior the start of the study.

Keywords: inulin-type fructans hemodialysis gut microbiome mineral and bone disorder
negative pressure wound therapy with instillation of saline solution versus collagenase ointment in full-thickness wounds

Conditions: Wounds and Injuries; Wound Healing; Granulation Tissue

Summary: evaluation of wound bed surface area containing clean, healthy viable tissue in full-thickness wounds.

this study evaluates changes in wound bed surface area of clean, healthy viable tissue in subjects with full-thickness wounds using negative pressure wound therapy with instillation of saline solution versus a collagenase ointment.

Eligibility criteria:
inclusion criteria: the subject: 1. is anticipated to be hospitalized for the duration of treatment (minimum of 6 days). 2. is ≥ 18 years of age. 3. or their legally authorized representative is able to provide informed consent. 4. has been diagnosed with a wound (eg, chronic, acute, traumatic, or dehisced wounds) and/or ulcer (ie, full- thickness wounds) that meets the following criteria: 1. total surface area measuring ≥ 16 cm2, including a minimum width of 2 cm (before removal of eschar at the bedside and excluding undermining). 2. \< 20 cm across (edge-to-edge) at any point perpendicular to the wound edges. 5. has, in the opinion of the investigator, no more than 2/3 of the wound bed surface area considered to be clean, healthy, and viable. if eschar is present at baseline, it must be removed by bedside debridement prior to assessing the percentage of clean, healthy, and viable wound bed. 6. has a negative urine or serum pregnancy test at screening (if female and has potential for pregnancy) and is willing to take precautionary measures to prevent pregnancy during the duration of the study (up to 9 days). exclusion criteria: the subject: 1. has been diagnosed with malignancy in the wound. 2. has untreated osteomyelitis. 3. has an untreated systemic infection. 4. has active cellulitis in the periwound area. 5. has a known allergy or hypersensitivity to study materials: collagenase ointment, dressing(s), and/or dressing components such as acrylic adhesives or polyurethane. 6. has, in the opinion of the investigator, a clinically significant condition that would impair the subject's ability to comply with the study procedures. 7. has had radiation directly to the wound area. 8. has been diagnosed with a major vascular deficit limiting arterial inflow to the wound region, as determined by the investigator's interpretation of the subject's medical history. 9. has eschar in the wound that cannot be removed by bedside sharp and/or mechanical debridement. 10. is participating in another interventional clinical trial for the duration of the study. 11. has unexplored fistulas in the wound or fistulas in the wound that connect to other body cavities. 12. has a wound with any tunneling present. 13. has inadequate hemostasis at the wound site, as determined by the investigator.
zeiss resight disposable lenses evaluation study

Conditions: Retinal Detachment; Macular Pucker; Macular Holes; Vitreomacular Traction

Summary: to evaluate the intra-operative efficacy of a new intra-operative viewing device.

this study is designed to obtain more information on the efficacy of the disposable resight lenses in routine vitrectomy surgery. this information can lead to adjustments to these surgical lenses to further fine tune a device which can be used by other surgeons. theoretically, both the improved lens design and better resistance to fogging should improve the visualization of the retina hence facilitate the surgery, increasing the surgical safety.

Eligibility criteria:
inclusion criteria: * voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures * patients that are scheduled for primary vitrectomy surgery to treat retinal detachment or macular disease (pucker, macular hole, vitreomacular traction). * both vitrectomy-only and combined phaco-vitrectomy surgeries * general or local anesthesia, or combination exclusion criteria: * patient who do not have sufficient command of the dutch language to read and understand the informed consent form * any disorder, which in the investigator's opinion might jeopardise participant's safety or compliance with the cip. * repeat vitrectomy surgery
index of microcirculatory resistance after drug-eluting stent implantation with high dose atorvastatin loading

Conditions: Acute Coronary Syndrome

Summary: pre-treatment with statins decreased the incidence of cardiac enzyme increase after percutaneous coronary intervention (pci) and distal embolization suspected to cause post-pci myocardial damage. this study evaluates the effect of high dose atorvastatin pre-treatment on post-procedural index of microcirculatory resistance (imr) values that are introduced for assessing the status of the microcirculation.

one hundred patients with non-st elevation acute coronary syndrome will be randomly assigned to either high dose atorvastatin pre-treatment group(80 mg loading within 24 hours plus 40mg busting within 2 hours before pci) or control group(atorvastatin 10mg administration within 24 hours before pci). an intracoronary pressure/temperature sensor-tipped guidewire is used. thermodilution curves are obtained during maximal hyperemia. the imr was calculated from the ratio of the mean distal coronary pressure at maximal hyperemia to the inverse of mean hyperemic transit time. creatine kinase-myocardial band(ck-mb) and crp level will be measured at baseline and at 12\~24 hours after pci.

Eligibility criteria:
inclusion criteria: * patients of non-st elevation acute coronary syndrome planed to elective percutaneous coronary intervention exclusion criteria: * st elevation myocardial infarction * cardiogenic shock * congestive heart failure with pulmonary edema * severe left ventricular dysfunction (lvef \< 30%) * history of previous coronary revascularization therapy * chronic total coronary occlusion * 3 vessel disease * target lesion at distal segments or branches * ostial lesion * excessive coronary calcification or thrombi * elevated transaminase * renal dysfunction (serum creatinine \> 2.0mg/dl * history of myopathy * contra-indication to anti-platelet therapy * not indicated for percutaneous coronary intervention * other co-morbidity with life expectancy less than 1 year

Keywords: index of microcirculatory resistance atorvastatin drug-eluting stent acute coronary syndrome
right ventricular function at rest in highlanders/lowlanders

Conditions: High Altitude Pulmonary Hypertension

Summary: the purpose of the current study is to evaluate the progression of right ventricular function and dimension in kyrgyz highlanders with high altitude pulmonary hypertension (haph) by performing a cross sectional case-control study.


Eligibility criteria:
inclusion criteria: * high altitude pulmonary hypertension confirmed by clinical presentation and mean pulmonary artery pressure \>30 mmhg measured by echocardiography at altitude of residence. * healthy subjects (high altitude controls) * both genders * age \>16 y * kyrgyz ethnicity * born, raised and currently living at \>2500 m * healthy subjects currently living at \<1000 m (low altitude controls) exclusion criteria: * pulmonary hypertension from other causes, in particular from left ventricular failure as judged clinically and by echocardiography * excessive erythrocytosis * other coexistent disorders that may interfere with the cardio-respiratory system and sleep * regular use of medication that affects control of breathing * heavy smoking

Keywords: echocardiography right ventricular function pulmonary hypertension disease progression hypoxia
unmasking right ventricular and pulmonary derangements with exercise and oxygen in early stage cardiopulmonary diseases

Conditions: Cardiopulmonary Disease

Summary: researchers are trying to develop innovative strategies that target the early identification heart and lung imbalances in patients with cardiopulmonary diseases.


Eligibility criteria:
inclusion criteria: * healthy controls (no known cardiac or pulmonary disease); * pah/hfpef patients with known rv failure; * pah/hfpef patients with known pulmonary failure * newly diagnosed pah/hfpef patients without any evidence of profound rv or pulmonary dysfunction. exclusion criteria: * persons unable to perform light exercise * persons pregnant or planning to be pregnant
preoperative survey to evaluate patient allergy

Conditions: Allergy Drug; Allergic Reaction; Pediatric; Surgery

Summary: the study will only involve identification of the listed allergies from the electronic medical record and investigation into the symptoms that prompted this allergy listing. the purpose is to evaluate demographics and prevalence of allergies in patients presenting for surgery, evaluate the medical decision making process behind allergy identification, and determine its potential impact on perioperative care. the participants will be asked to complete a survey in redcap using an ipad during the visit.


Eligibility criteria:
inclusion criteria: * patients 0-21 years of age presenting for surgery or procedure requiring anesthesia exclusion criteria: * patients who are not able cognitively to complete the computerized survey due to physical or intellectual impairment or communication issues related to non-english speaking patients
efficacy, safety and tolerability of atorvastatin 40 mg in patients with relapsing-remitting multiple sclerosis treated with interferon-beta-1b

Conditions: Relapsing-remitting Multiple Sclerosis

Summary: the "swiss atorvastatin and interferon-beta 1b trial in multiple sclerosis - follow up study" is the follow up study of the "swiss atorvastatin and interferon beta-1b trial in multiple sclerosis (swabims)" (see http://www.clinicaltrials.gov. identifier: nct00942591) swabims evaluated the efficacy, safety and tolerability of atorvastatin 40 mg in addition to interferon-beta 1b compared to interferon-beta 1b monotherapy in patients with relapsing-remitting multiple sclerosis for 15 month. the swabims follow up study observes patients that finish the swabims study for another 12 month with ongoing unchanged medication.

background multiple sclerosis is a chronic inflammatory autoimmune disease of the central nervous system. statins are lipid-lowering drugs which inhibit the 3-hydroxy-3-methylglutaryl-coenzyme a (hmg-coa-) reductase, which is the main regulatory enzyme of cholesterol biosynthesis. in recent years many studies have demonstrated, that statins have anti-inflammatory and immunomodulatory properties in addition to their lipid-lowering effects. therefore, statins may have therapeutic potential in immune-mediated disorders such as multiple sclerosis. studies in experimental allergic encephalomyelitis (eae), the animal model for the human demyelinating disease multiple sclerosis, as well as smaller studies in patients with relapsing-remitting multiple sclerosis showed beneficial effect on the course of the disease. but there are also reports of negative impact of statins on multiple sclerosis. therefore, bigger studies are needed to investigate the therapeutical potential of statins in multiple sclerosis. objective to assess the efficacy, safety and tolerability of the combination of atorvastatin 40mg p.o. daily and interferon-beta 1b sc e.o.d compared to monotherapy with interferon-beta-1b sc e.o.d in patients with relapsing-remitting multiple sclerosis for 12 month after completing the swabims study. methods multi-center, rater-blinded, parallel-group, two arm, randomized study. patients with relapsing-remitting forms of ms, respecting all inclusion/exclusion criteria, were randomized in the swabims study in two equal-size parallel arms after three months of treatment with interferon-beta 1b, receiving atorvastatin 40mg/d or not in addition to interferon-beta 1b for 12 month. after successful completion of the study, patients were asked to participate in the "swabims follow up study" for another 12 month with ongoing medication.

Eligibility criteria:
inclusion criteria: * successful completion of the swabims study * written informed consent exclusion criteria * any disease other than multiple sclerosis that would better explain the patient's signs and symptoms * secondary progressive ms * uncontrolled severe medical disorder * participation in any other studies

Keywords: multi-center randomized prospective parallel-group rater-blinded rr-ms